Trademark Overview
On Thursday, July 25, 2024, a trademark application was filed for IDEA TO CLINIC with the United States Patent and Trademark Office. The USPTO has given the IDEA TO CLINIC trademark a serial number of 98667074. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, February 11, 2025. This trademark is owned by National Resilience, Inc.. The IDEA TO CLINIC trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:
Custom manufacturing of pharmaceuticals, biological preparations, chemical preparations, and reagents for others; biomanufacturing for others, namely, manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; biomanufacturing platform for others, namely, manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; consulting services in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; custom processing and manufacture of vectors, cells and proteins for use in the field of biotechnology
Research, development, and consulting services related thereto in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; genetic engineering services; biotechnology research and development; scientific, pharmaceutical, and medical research services relating to biological treatment and bioproduction; design and development of technology platforms relating to biological treatment for use in the manufacture of pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; provision of information relating to research and development of biopharmaceuticals that are manufactured using biological treatment and bioproduction platforms; development of new technology for others in the field of biotechnology, biomanufacturing, and pharmaceuticals; new product design ser...
